Difference between revisions of "Cutaneous T-cell lymphoma - null regimens"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "While not clinically relevant, these references provide further insight into the historical development of the treatment landscape" to "These references provide further insight into the historical development of the treatment landscape") |
Warner-admin (talk | contribs) m (Text replacement - "]] for current regimens." to "]] for regimens that include active anticancer treatment.") |
||
| Line 3: | Line 3: | ||
[[#top|Back to Top]] | [[#top|Back to Top]] | ||
</div> | </div> | ||
| − | The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Cutaneous T-cell lymphoma|main CTCL page]] for | + | The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Cutaneous T-cell lymphoma|main CTCL page]] for regimens that include active anticancer treatment. |
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
Revision as of 12:39, 14 October 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main CTCL page for regimens that include active anticancer treatment.
Relapsed or refractory
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Prince et al. 2010 (L4389-11) | NR | Phase 3 (C) | Denileukin diftitox | Inferior PFS |
References
- L4389-11: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870-7. Epub 2010 Mar 8. link to original article contains dosing details in manuscript PubMed NCT00050999